Allogeneic Hematopoietic Stem Cell Transplantation

In childhood leukemia, hematopoietic stem cell transplantation (HSCT) is often included in the comprehensive treatment plan when there is a high risk of recurrence, relapse/refractory disease, or unstable remission. The decision considers disease classification and staging, minimal residual disease (MRD), previous treatment response, organ function and infection status, and whether there are suitable donors and graft sources (including HLA-matched related/unrelated donors, haploidentical, and umbilical cord blood, etc.).